Jump to content

Stem cell

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 198.151.130.153 (talk) at 18:35, 19 November 2013 (→Significant Disadvantages). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

This article is about the cell type. For the medical therapy, see Stem cell treatment.
Stem cell
Adult stem cell displaying typical ultrastructural characteristics.
Details
Identifiers
LatinCellula praecursoria
MeSHD013234
THH1.00.01.0.00028, H2.00.01.0.00001
FMA63368
Anatomical terminology

Stem cells are undifferentiated biological cells, that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. They are found in multicellular organisms. In mammals, there are two broad types of stem cells: embryonic stem cells, which are isolated from the inner cell mass of blastocysts, and adult stem cells, which are found in various tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing adult tissues. In a developing embryo, stem cells can differentiate into all the specialized cells—ectoderm, endoderm and mesoderm (see induced pluripotent stem cells)—but also maintain the normal turnover of regenerative organs, such as blood, skin, or intestinal tissues.

There are three accessible sources of autologous adult stem cells in humans:

  1. Bone marrow, which requires extraction by harvesting, that is, drilling into bone (typically the femur or iliac crest),
  2. Adipose tissue (lipid cells), which requires extraction by liposuction, and
  3. Blood, which requires extraction through apheresis, wherein blood is drawn from the donor (similar to a blood donation), passed through a machine that extracts the stem cells and returns other portions of the blood to the donor.

Stem cells can also be taken from umbilical cord blood just after birth. Of all stem cell types, autologous harvesting involves the least risk. By definition, autologous cells are obtained from one's own body, just as one may bank his or her own blood for elective surgical procedures.

Highly plastic adult stem cells are routinely used in medical therapies, for example in bone marrow transplantation. Stem cells can now be artificially grown and transformed (differentiated) into specialized cell types with characteristics consistent with cells of various tissues such as muscles or nerves through cell culture. Embryonic cell lines and autologous embryonic stem cells generated through therapeutic cloning have also been proposed as promising candidates for future therapies.[1] Research into stem cells grew out of findings by Ernest A. McCulloch and James E. Till at the University of Toronto in the 1960s.[2][3]

Properties

The classical definition of a stem cell requires that it possess two properties:

  • Self-renewal: the ability to go through numerous cycles of cell division while maintaining the undifferentiated state.
  • Potency: the capacity to differentiate into specialized cell types. In the strictest sense, this requires stem cells to be either totipotent or pluripotent—to be able to give rise to any mature cell type, although multipotent or unipotent progenitor cells are sometimes referred to as stem cells. Apart from this it is said that stem cell function is regulated in a feed back mechanism.

Self-renewal

Two mechanisms exist to ensure that a stem cell population is maintained:

  1. Obligatory asymmetric replication: a stem cell divides into one mother cell that is identical to the original stem cell, and another daughter cell that is differentiated
  2. Stochastic differentiation: when one stem cell develops into two differentiated daughter cells, another stem cell undergoes mitosis and produces two stem cells identical to the original.

Potency definitions

Main article: Cell potency
Pluripotent, embryonic stem cells originate as inner cell mass (ICM) cells within a blastocyst. These stem cells can become any tissue in the body, excluding a placenta. Only cells from an earlier stage of the embryo, known as the morula, are totipotent, able to become all tissues in the body and the extraembryonic placenta.
Human embryonic stem cells
A: Cell colonies that are not yet differentiated.
B: Nerve cell

Potency specifies the differentiation potential (the potential to differentiate into different cell types) of the stem cell.[4]

  • Totipotent (a.k.a. omnipotent) stem cells can differentiate into embryonic and extraembryonic cell types. Such cells can construct a complete, viable organism.[4] These cells are produced from the fusion of an egg and sperm cell. Cells produced by the first few divisions of the fertilized egg are also totipotent.[5]
  • Pluripotent stem cells are the descendants of totipotent cells and can differentiate into nearly all cells,[4] i.e. cells derived from any of the three germ layers.[6]
  • Multipotent stem cells can differentiate into a number of cells, but only those of a closely related family of cells.[4]
  • Oligopotent stem cells can differentiate into only a few cells, such as lymphoid or myeloid stem cells.[4]
  • Unipotent cells can produce only one cell type, their own,[4] but have the property of self-renewal, which distinguishes them from non-stem cells (e.g. progenitor cells, muscle stem cells).

Identification

The practical definition of a stem cell is the functional definition—a cell that has the potential to regenerate tissue over a lifetime. For example, the defining test for a bone marrow or hematopoietic stem cell (HSC) is the ability to transplant one cell and save an individual without HSCs. In this case, a stem cell must be able to produce new blood cells and immune cells over a long term, demonstrating potency. It should also be possible to isolate stem cells from the transplanted individual, which can themselves be transplanted into another individual without HSCs, demonstrating that the stem cell was able to self-renew.

Properties of stem cells can be illustrated in vitro, using methods such as clonogenic assays, in which single cells are assessed for their ability to differentiate and self-renew.[7][8] Stem cells can also be isolated by their possession of a distinctive set of cell surface markers. However, in vitro culture conditions can alter the behavior of cells, making it unclear whether the cells will behave in a similar manner in vivo. There is considerable debate as to whether some proposed adult cell populations are truly stem cells.

Embryonic

Main article: Embryonic stem cell

Embryonic stem (ES) cell lines are cultures of cells derived from the epiblast tissue of the inner cell mass (ICM) of a blastocyst or earlier morula stage embryos.[9] A blastocyst is an early stage embryo—approximately four to five days old in humans and consisting of 50–150 cells. ES cells are pluripotent and give rise during development to all derivatives of the three primary germ layers: ectoderm, endoderm and mesoderm. In other words, they can develop into each of the more than 200 cell types of the adult body when given sufficient and necessary stimulation for a specific cell type. They do not contribute to the extra-embryonic membranes or the placenta. The endoderm is composed of the entire gut tube and the lungs, the ectoderm gives rise to the nervous system and skin, and the mesoderm gives rise to muscle, bone, blood—in essence, everything else that connects the endoderm to the ectoderm.

Nearly all research to date has made use of mouse embryonic stem cells (mES) or human embryonic stem cells (hES). Both have the essential stem cell characteristics, yet they require very different environments in order to maintain an undifferentiated state. Mouse ES cells are grown on a layer of gelatin as an extracellular matrix (for support) and require the presence of leukemia inhibitory factor (LIF). Human ES cells are grown on a feeder layer of mouse embryonic fibroblasts (MEFs) and require the presence of basic fibroblast growth factor (bFGF or FGF-2).[10] Without optimal culture conditions or genetic manipulation,[11] embryonic stem cells will rapidly differentiate.

A human embryonic stem cell is also defined by the expression of several transcription factors and cell surface proteins. The transcription factors Oct-4, Nanog, and Sox2 form the core regulatory network that ensures the suppression of genes that lead to differentiation and the maintenance of pluripotency.[12] The cell surface antigens most commonly used to identify hES cells are the glycolipids stage specific embryonic antigen 3 and 4 and the keratan sulfate antigens Tra-1-60 and Tra-1-81. The molecular definition of a stem cell includes many more proteins and continues to be a topic of research.[13]

There are currently no approved treatments using embryonic stem cells. The first human trial was approved by the US Food and Drug Administration in January 2009.[14] However, the human trial was not initiated until October 13, 2010 in Atlanta for spinal injury victims. On November 14, 2011 the company conducting the trial announced that it will discontinue further development of its stem cell programs.[15] ES cells, being pluripotent cells, require specific signals for correct differentiation—if injected directly into another body, ES cells will differentiate into many different types of cells, causing a teratoma. Differentiating ES cells into usable cells while avoiding transplant rejection are just a few of the hurdles that embryonic stem cell researchers still face.[16] Many nations currently have moratoria on either ES cell research or the production of new ES cell lines. Because of their combined abilities of unlimited expansion and pluripotency, embryonic stem cells remain a theoretically potential source for regenerative medicine and tissue replacement after injury or disease.

  • Mouse embryonic stem cells with fluorescent marker
    Mouse embryonic stem cells with fluorescent marker
  • Human embryonic stem cell colony on mouse embryonic fibroblast feeder layer
    Human embryonic stem cell colony on mouse embryonic fibroblast feeder layer

Fetal

The primitive stem cells located in the organs of fetuses are referred to as fetal stem cells.[17] There are two types of stem cells that are referred to as Fetal stem cells, they are fetal proper stem cells, and extraembryonic fetal stem cells.

→Fetal proper stem cells come from the tissue of the fetus proper, and they are generally obtained after an abortion. These stem cells are not immortal but have a high level of division and are multipotent.

→Extraembryonic fetal stem cells come from extraembryonic membranes, and are generally not distinguished from adult stem cells. These stem cells are acquired after birth, they are not immortal but have a high level of cell division, and are pluripotent.[18]

Adult

Main article: Adult stem cell
Stem cell division and differentiation. A: stem cell; B: progenitor cell; C: differentiated cell; 1: symmetric stem cell division; 2: asymmetric stem cell division; 3: progenitor division; 4: terminal differentiation

Also known as somatic (from Greek Σωματικóς, "of the body") stem cells and germline (giving rise to gametes) stem cells, they can be found in children, as well as adults.[19]

The Primary roles of adult stem cells in a living organism is to maintain and repair the tissue in which they are found.[20]

Pluripotent adult stem cells are rare and generally small in number but can be found in a number of tissues including umbilical cord blood.[21] Bone marrow has been found to be one of the rich sources of adult stem cells [22] which have been used in treating several conditions including Spinal cord injury,[23] Liver Cirrhosis,[24] Chronic Limb Ischemia [25] and Endstage heart failure.[26] The bone marrow stem cell quantity has been found to be declining with age and in reproductive age group of females it is relatively lesser than in males of same age group.[27] A great deal of adult stem cell research to date has had the aim of characterizing the capacity of the cells to divide or self-renew indefinitely and their differentiation potential.[28] In mice, pluripotent stem cells are directly generated from adult fibroblast cultures. Unfortunately, many mice do not live long with stem cell organs.[29]

Most adult stem cells are lineage-restricted (multipotent) and are generally referred to by their tissue origin (mesenchymal stem cell, adipose-derived stem cell, endothelial stem cell, dental pulp stem cell, etc.).[30][31]

Adult stem cell treatments have been successfully used for many years to treat leukemia and related bone/blood cancers through bone marrow transplants.[32] Adult stem cells are also used in veterinary medicine to treat tendon and ligament injuries in horses.[33]

The use of adult stem cells in research and therapy is not as controversial as the use of embryonic stem cells, because the production of adult stem cells does not require the destruction of an embryo. Additionally, in instances where adult stem cells are obtained from the intended recipient (an autograft), the risk of rejection is essentially non-existent. Consequently, more US government funding is being provided for adult stem cell research.[34]

An extremely rich source for adult mesenchymal stem cells is the developing tooth bud of the mandibular third molar.[35] The stem cells eventually form enamel (ectoderm), dentin, periodontal ligament, blood vessels, dental pulp, nervous tissues, and a minimum of 29 different end organs. Because of extreme ease in collection at 8–10 years of age before calcification and minimal to no morbidity, these will probably constitute a major source of cells for personal banking, research and current or future therapies. These stem cells have been shown capable of producing hepatocytes.[citation needed]

Amniotic

Multipotent stem cells are also found in amniotic fluid. These stem cells are very active, expand extensively without feeders and are not tumorigenic. Amniotic stem cells are multipotent and can differentiate in cells of adipogenic, osteogenic, myogenic, endothelial, hepatic and also neuronal lines.[36] All over the world, universities and research institutes are studying amniotic fluid to discover all the qualities of amniotic stem cells, and scientists such as Anthony Atala[37][38] and Giuseppe Simoni [39][40] have discovered important results.

Use of stem cells from amniotic fluid overcomes the ethical objections to using human embryos as a source of cells. Roman Catholic teaching forbids the use of embryonic stem cells in experimentation; accordingly, the Vatican newspaper "Osservatore Romano" called amniotic stem cells "the future of medicine".[41]

It is possible to collect amniotic stem cells for donors or for autologuous use: the first US amniotic stem cells bank [42][43] was opened in 2009 in Medford, MA, by Biocell Center Corporation[44][45][46] and collaborates with various hospitals and universities all over the world.[47]

Cord blood

Main article: Cord blood-derived multipotent stem cell

A certain kind of cord blood stem cell (CB-SC) is multipotent and displays embryonic and hematopoietic characteristics. Phenotypic characterization demonstrates that (CB-SCs) display embryonic cell markers (e.g., transcription factors OCT-4 and Nanog, stage-specific embryonic antigen (SSEA)-3, and SSEA-4) and leukocyte common antigen CD45, but that they are negative for blood cell lineage markers (e.g., CD1a, CD3, CD4, CD8, CD11b, CD11c, CD13, CD14, CD19, CD20, CD34, CD41a, CD41b, CD83, CD90, CD105, and CD133).[48][49]

Additionally, CB-SCs display very low immunogenicity as indicated by expression of a very low level of major histocompatibility complex (MHC) antigens and failure to stimulate the proliferation of allogeneic lymphocytes.[48][50] They can give rise to three embryonic layer-derived cells in the presence of different inducers.[48][51]

More specifically, CB-SCs tightly adhere to culture dishes with a large rounded morphology and are resistant to common detaching methods (trypsin/EDTA).[48][50][51] CB-SCs are the active agent in stem cell educator therapy, which has therapeutic potential against autoimmune diseases like type 1 diabetes according to studies by Yong Zhao et al.[49][52][53][54][unreliable medical source?]

Induced pluripotent

Main article: Induced pluripotent stem cell

These are not adult stem cells, but rather adult cells (e.g. epithelial cells) reprogrammed to give rise to pluripotent capabilities. Using genetic reprogramming with protein transcription factors, pluripotent stem cells equivalent to embryonic stem cells have been derived from human adult skin tissue.[55][56][57] Shinya Yamanaka and his colleagues at Kyoto University used the transcription factors Oct3/4, Sox2, c-Myc, and Klf4[55] in their experiments on cells from human faces. Junying Yu, James Thomson, and their colleagues at the University of Wisconsin–Madison used a different set of factors, Oct4, Sox2, Nanog and Lin28,[55] and carried out their experiments using cells from human foreskin.

As a result of the success of these experiments, Ian Wilmut, who helped create the first cloned animal Dolly the Sheep, has announced that he will abandon somatic cell nuclear transfer as an avenue of research.[58]

Frozen blood samples can be used as a source of induced pluripotent stem cells, opening a new avenue for obtaining the valued cells.[59]

Lineage

Main article: Stem cell line

To ensure self-renewal, stem cells undergo two types of cell division (see Stem cell division and differentiation diagram). Symmetric division gives rise to two identical daughter cells both endowed with stem cell properties. Asymmetric division, on the other hand, produces only one stem cell and a progenitor cell with limited self-renewal potential. Progenitors can go through several rounds of cell division before terminally differentiating into a mature cell. It is possible that the molecular distinction between symmetric and asymmetric divisions lies in differential segregation of cell membrane proteins (such as receptors) between the daughter cells.[60]

An alternative theory is that stem cells remain undifferentiated due to environmental cues in their particular niche. Stem cells differentiate when they leave that niche or no longer receive those signals. Studies in Drosophila germarium have identified the signals decapentaplegic and adherens junctions that prevent germarium stem cells from differentiating.[61][62]

Main article: Induced pluripotent stem cell

The signals that lead to reprogramming of cells to an embryonic-like state are also being investigated. These signal pathways include several transcription factors including the oncogene c-Myc. Initial studies indicate that transformation of mice cells with a combination of these anti-differentiation signals can reverse differentiation and may allow adult cells to become pluripotent.[29] However, the need to transform these cells with an oncogene may prevent the use of this approach in therapy.

Main article: Induced stem cells

Challenging the terminal nature of cellular differentiation and the integrity of lineage commitment, it was recently determined that the somatic expression of combined transcription factors can directly induce other defined somatic cell fates; researchers identified three neural-lineage-specific transcription factors that could directly convert mouse fibroblasts (skin cells) into fully functional neurons. This "induced neurons" (iN) cell research inspires the researchers to induce other cell types. It implies that all cells are totipotent: with the proper tools, all cells may form all kinds of tissue.[63]

Treatments

Main article: Stem cell treatments
Diseases and conditions where stem cell treatment is promising or emerging.[64] Bone marrow transplantation is, as of 2009, the only established use of stem cells.

Medical researchers believe that stem cell therapy has the potential to dramatically change the treatment of human disease. A number of adult stem cell therapies already exist, particularly bone marrow transplants that are used to treat leukemia.[65] In the future, medical researchers anticipate being able to use technologies derived from stem cell research to treat a wider variety of diseases including cancer, Parkinson's disease, spinal cord injuries, Amyotrophic lateral sclerosis, multiple sclerosis, and muscle damage, amongst a number of other impairments and conditions.[66][67] However, there still exists a great deal of social and scientific uncertainty surrounding stem cell research, which could possibly be overcome through public debate and future research, and further education of the public.

One concern of treatment is the risk that transplanted stem cells could form tumors and become cancerous if cell division continues uncontrollably.[68]

Stem cells are widely studied, for their potential therapeutic use and for their inherent interest.[69]

Supporters of embryonic stem cell research argue that such research should be pursued because the resultant treatments could have significant medical potential. It has been proposed that surplus embryos created for in vitro fertilization could be donated with consent and used for the research.

The recent development of iPS cells has been called a bypass of the legal controversy. Laws limiting the destruction of human embryos have been credited for being the reason for development of iPS cells, but it is still not completely clear whether hiPS cells are equivalent to hES cells. Recent work demonstrates hotspots of aberrant epigenomic reprogramming in hiPS cells (Lister, R., et al., 2011).

Significant Disadvantages

Although stem cells can be very beneficial for treatments of many disorders and diseases they can also have negative effects on human health, such as causing tumors or leading to immune suppression. Pluripotency in certain stem cells could also make it difficult to obtain a specific cell type.

·Tumors Some stem cells form tumors when implanted in body, pluripotency is linked to tumor formation especially in embryonic stem cells, fetal proper stem cells, induced pluripotent stem cells. Fetal proper stem cells form tumors despite multipotency.

·Immune rejection The human body attacks cells that come form non-native sources, and since most stem cell treatments come from non-native sources this could cause problems. Immune rejection is found in embryonic stem cells, fetal proper stem cells. No immune rejection is found in extraembryonic fetal stem cells, adult stem cells, and induced pluripotent stem cells. Cells can be used from same patient that is being treated. Extraembryonic fetals stem cells and adult stem cells may not be rejected even if used from non-native source.

·Pluripotency Makes it difficult to obtain exact cell type needed, because not all cells in a population differentiate uniformly. Undifferentiated cells can create tissues other than desired types. [70]

Toxicity screening

Hepatotoxicity and drug-induced liver injury account for a substantial number of failures of new drugs in development and market withdrawal, highlighting the need for screening assays such as stem cell-derived hepatocyte-like cells, that are capable of detecting toxicity early in the drug development process.[71]

Research patents

The patents covering a lot of work on human embryonic stem cells are owned by the Wisconsin Alumni Research Foundation (WARF). WARF does not charge academics to study human stem cells but does charge commercial users. WARF sold Geron Corp. exclusive rights to work on human stem cells but later sued Geron Corp. to recover some of the previously sold rights. The two sides agreed that Geron Corp. would keep the rights to only three cell types. In 2001, WARF came under public pressure to widen access to human stem-cell technology.[72]

A request for reviewing the WARF patents 5,843,780; 6,200,806; 7,029,913 US Patent and Trademark Office were filed by non-profit patent-watchdogs The Foundation for Taxpayer & Consumer Rights, and the Public Patent Foundation as well as molecular biologist Jeanne Loring of the Burnham Institute. According to them, two of the patents granted to WARF are invalid because they cover a technique published in 1993 for which a patent had already been granted to an Australian researcher. Another part of the challenge states that these techniques, developed by James A. Thomson, are rendered obvious by a 1990 paper and two textbooks. Based on this challenge, patent 7,029,913 was rejected in 2010. The two remaining hES WARF patents are due to expire in 2015.

The outcome of this legal challenge is particularly relevant to the Geron Corp. as it can only license patents that are upheld.[73]

Key research events

  • 1908: The term "stem cell" was proposed for scientific use by the Russian histologist Alexander Maksimov (1874–1928) at congress of hematologic society in Berlin. It postulated existence of haematopoietic stem cells.
  • 1960s: Joseph Altman and Gopal Das present scientific evidence of adult neurogenesis, ongoing stem cell activity in the brain; their reports contradict Cajal's "no new neurons" dogma and are largely ignored.
  • 1963: McCulloch and Till illustrate the presence of self-renewing cells in mouse bone marrow.
  • 1968: Bone marrow transplant between two siblings successfully treats SCID.
  • 1978: Haematopoietic stem cells are discovered in human cord blood.
  • 1981: Mouse embryonic stem cells are derived from the inner cell mass by scientists Martin Evans, Matthew Kaufman, and Gail R. Martin. Gail Martin is attributed for coining the term "Embryonic Stem Cell".
  • 1992: Neural stem cells are cultured in vitro as neurospheres.
  • 1995: Dr. B.G. Matapurkar pioneers in adult stem-cell research with clinical utilization of research in the body and neo-regeneration of tissues and organs in the body. Received International Patent from US Patent Office (USA) in 2001 (effective from 1995). Clinical utilization in human body also demonstrated and patented in 60 patients (World Journal of Surgery-1999[74] and 1991[75]).
  • 1997: Dr. B.G. Matapurkar's surgical technique on regeneration of tissues and organs is published.[76] Regeneration of faellopian tube and uterus is published.[77]
  • 1997: Leukemia is shown to originate from a haematopoietic stem cell, the first direct evidence for cancer stem cells.
  • 1998: James Thomson and coworkers derive the first human embryonic stem cell line at the University of Wisconsin–Madison.[78]
  • 1998: John Gearhart (Johns Hopkins University) extracted germ cells from fetal gonadal tissue (primordial germ cells) before developing pluripotent stem cell lines from the original extract.
  • 2000s: Several reports of adult stem cell plasticity are published.
  • 2001: Scientists at Advanced Cell Technology clone first early (four- to six-cell stage) human embryos for the purpose of generating embryonic stem cells.[79]
  • 2003: Dr. Songtao Shi of NIH discovers new source of adult stem cells in children's primary teeth.[80]
  • 2004–2005: Korean researcher Hwang Woo-Suk claims to have created several human embryonic stem cell lines from unfertilised human oocytes. The lines were later shown to be fabricated.
  • 2005: Researchers at Kingston University in England claim to have discovered a third category of stem cell, dubbed cord-blood-derived embryonic-like stem cells (CBEs), derived from umbilical cord blood. The group claims these cells are able to differentiate into more types of tissue than adult stem cells.
  • 2005: Researchers at UC Irvine's Reeve-Irvine Research Center are able to partially restore the ability of rats with paralyzed spines to walk through the injection of human neural stem cells.[81]
Yong Zhao, University of Illinois at Chicago
  • April 2006 Scientists at the University of Illinois at Chicago identified novel stem cells from the umbilical cord blood with embryonic and hematopoietic characteristics.[48]
  • August 2006: Mouse Induced pluripotent stem cells: the journal Cell publishes Kazutoshi Takahashi and Shinya Yamanaka.[29]
  • November 2006: Yong Zhao et al. revealed the immune regulation of T lymphocytes by Cord Blood-Derived Multipotent Stem Cells (CB-SCs).[50]
  • October 2006: Scientists at Newcastle University in England create the first ever artificial liver cells using umbilical cord blood stem cells.[82][83]
  • January 2007: Scientists at Wake Forest University led by Dr. Anthony Atala and Harvard University report discovery of a new type of stem cell in amniotic fluid.[84] This may potentially provide an alternative to embryonic stem cells for use in research and therapy.[85]
  • June 2007: Research reported by three different groups shows that normal skin cells can be reprogrammed to an embryonic state in mice.[86] In the same month, scientist Shoukhrat Mitalipov reports the first successful creation of a primate stem cell line through somatic cell nuclear transfer[87]
    Martin Evans, a co-winner of the Nobel Prize in recognition of his gene targeting work.
  • October 2007: Mario Capecchi, Martin Evans, and Oliver Smithies win the 2007 Nobel Prize for Physiology or Medicine for their work on embryonic stem cells from mice using gene targeting strategies producing genetically engineered mice (known as knockout mice) for gene research.[88]
  • November 2007: Human induced pluripotent stem cells: Two similar papers released by their respective journals prior to formal publication: in Cell by Kazutoshi Takahashi and Shinya Yamanaka, "Induction of pluripotent stem cells from adult human fibroblasts by defined factors",[89] and in Science by Junying Yu, et al., from the research group of James Thomson, "Induced pluripotent stem cell lines derived from human somatic cells":[90] pluripotent stem cells generated from mature human fibroblasts. It is possible now to produce a stem cell from almost any other human cell instead of using embryos as needed previously, albeit the risk of tumorigenesis due to c-myc and retroviral gene transfer remains to be determined.
  • January 2008: Robert Lanza and colleagues at Advanced Cell Technology and UCSF create the first human embryonic stem cells without destruction of the embryo[91]
  • January 2008: Development of human cloned blastocysts following somatic cell nuclear transfer with adult fibroblasts[92]
  • February 2008: Generation of pluripotent stem cells from adult mouse liver and stomach: these iPS cells seem to be more similar to embryonic stem cells than the previously developed iPS cells and not tumorigenic, moreover genes that are required for iPS cells do not need to be inserted into specific sites, which encourages the development of non-viral reprogramming techniques.[93]
  • March 2008-The first published study of successful cartilage regeneration in the human knee using autologous adult mesenchymal stem cells is published by clinicians from Regenerative Sciences[94]
  • October 2008: Sabine Conrad and colleagues at Tübingen, Germany generate pluripotent stem cells from spermatogonial cells of adult human testis by culturing the cells in vitro under leukemia inhibitory factor (LIF) supplementation.[95]
  • 30 October 2008: Embryonic-like stem cells from a single human hair.[96]
  • January 2009: Yong Zhao and colleagues confirmed the reversal of autoimmune-caused type 1 diabetes by Cord Blood-Derived Multipotent Stem Cells (CB-SCs) in an animal experiment.[49][52]
  • 1 March 2009: Andras Nagy, Keisuke Kaji, et al. discover a way to produce embryonic-like stem cells from normal adult cells by using a novel "wrapping" procedure to deliver specific genes to adult cells to reprogram them into stem cells without the risks of using a virus to make the change.[97][98][99] The use of electroporation is said to allow for the temporary insertion of genes into the cell.[100][100][101][102]
  • 28 May 2009 Kim et al. announced that they had devised a way to manipulate skin cells to create patient specific "induced pluripotent stem cells" (iPS), claiming it to be the 'ultimate stem cell solution'.[103]
  • 11 October 2010 First trial of embryonic stem cells in humans.[104]
  • 25 October 2010: Ishikawa et al. write in the Journal of Experimental Medicine that research shows that transplanted cells that contain their new host's nuclear DNA could still be rejected by the invidual's immune system due to foreign mitochondrial DNA. Tissues made from a person's stem cells could therefore be rejected, because mitochondrial genomes tend to accumulate mutations.[105]
  • 2011: Israeli scientist Inbar Friedrich Ben-Nun led a team which produced the first stem cells from endangered species, a breakthrough that could save animals in danger of extinction.[106]
  • January 2012: The human clinical trial of treating type 1 diabetes with lymphocyte modification using Cord Blood-Derived Multipotent Stem Cells (CB-SCs) achieved an improvement of C-peptide levels, reduced the median glycated hemoglobin A1C (HbA1c) values, and decreased the median daily dose of insulin in both human patient groups with and without residual beta cell function.[53][54] Yong Zhao's Stem Cell Educator Therapy appears "so simple and so safe"[107]
  • October 2012: Positions of nucleosomes in mouse embryonic stem cells and the changes in their positions during differentiation to neural progenitor cells and embryonic fibroblasts are determined with single-nucleotide resolution.[108]
  • 2012: Katsuhiko Hayashi used mouse skin cells to create stem cells and then used these stem cells to create mouse eggs. These eggs were then fertilized and produced healthy baby offspring. These latter mice were able to have their own babies.[109]
  • 2013: First time lab grown meat made from muscle stem-cells has been cooked and tasted.[110]
  • 2013: First time mice adult cells were reprogrammed into stem cells in vivo.[111]

See also

References

  1. ^ Tuch BE (2006). "Stem cells—a clinical update". Australian Family Physician. 35 (9): 719–21. PMID 16969445.
  2. ^ Becker AJ, McCulloch EA, Till JE (1963). "Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells". Nature. 197 (4866): 452–4. doi:10.1038/197452a0. PMID 13970094.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ Siminovitch L, McCulloch EA, Till JE (1963). "The distribution of colony-forming cells among spleen colonies". Journal of Cellular and Comparative Physiology. 62 (3): 327–36. doi:10.1002/jcp.1030620313. PMID 14086156.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ a b c d e f Schöler, Hans R. (2007). "The Potential of Stem Cells: An Inventory". In Nikolaus Knoepffler, Dagmar Schipanski, and Stefan Lorenz Sorgner (ed.). Humanbiotechnology as Social Challenge. Ashgate Publishing. p. 28. ISBN 978-0-7546-5755-2.{{cite book}}: CS1 maint: multiple names: editors list (link)
  5. ^ Mitalipov S, Wolf D (2009). "Totipotency, pluripotency and nuclear reprogramming". Adv. Biochem. Eng. Biotechnol. Advances in Biochemical Engineering/Biotechnology. 114: 185–99. doi:10.1007/10_2008_45. ISBN 978-3-540-88805-5. PMC 2752493. PMID 19343304.
  6. ^ Ulloa-Montoya F, Verfaillie CM, Hu WS (2005). "Culture systems for pluripotent stem cells". J Biosci Bioeng. 100 (1): 12–27. doi:10.1263/jbb.100.12. PMID 16233846.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  7. ^ Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luria EA, Ruadkow IA (1974). "Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method". Experimental Hematology. 2 (2): 83–92. ISSN 0301-472X. PMID 4455512.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  8. ^ Friedenstein AJ, Gorskaja JF, Kulagina NN (1976). "Fibroblast precursors in normal and irradiated mouse hematopoietic organs". Experimental Hematology. 4 (5): 267–74. PMID 976387.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  9. ^ "New Stem-Cell Procedure Doesn't Harm Embryos, Company Claims". Associated Press via Fox News. 2006-08-24.
  10. ^ "Culture of Human Embryonic Stem Cells (hESC)". National Institutes of Health. Retrieved 2010-03-07.
  11. ^ Chambers I; Colby D; Robertson M; Nichols, Jennifer; Lee, Sonia; Tweedie, Susan; Smith, Austin (2003). "Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells". Cell. 113 (5): 643–55. doi:10.1016/S0092-8674(03)00392-1. PMID 12787505.
  12. ^ Boyer LA; Lee TI; Cole MF; Johnstone, Sarah E.; Levine, Stuart S.; Zucker, Jacob P.; Guenther, Matthew G.; Kumar, Roshan M.; Murray, Heather L. (2005). "Core transcriptional regulatory circuitry in human embryonic stem cells". Cell. 122 (6): 947–56. doi:10.1016/j.cell.2005.08.020. PMC 3006442. PMID 16153702.
  13. ^ Adewumi O; Aflatoonian B; Ahrlund-Richter L; Amit, Michal; Andrews, Peter W; Beighton, Gemma; Bello, Paul A; Benvenisty, Nissim; Berry, Lorraine S (2007). "Characterization of human embryonic stem cell lines by the International Stem Cell Initiative". Nat. Biotechnol. 25 (7): 803–16. doi:10.1038/nbt1318. PMID 17572666.
  14. ^ Ron Winslow (2009). "First Embryonic Stem-Cell Trial Gets Approval from the FDA". The Wall Street Journal. 23. January 2009.
  15. ^ "Embryonic Stem Cell Therapy At Risk? Geron Ends Clinical Trial". ScienceDebate.com. Retrieved 2011-12-11.
  16. ^ Wu DC, Boyd AS, Wood KJ (2007). "Embryonic stem cell transplantation: potential applicability in cell replacement therapy and regenerative medicine". Front Biosci. 12 (8–12): 4525–35. doi:10.2741/2407. PMID 17485394.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  17. ^ Ariff Bongso; Eng Hin Lee, ed. (2005). "Stem cells: their definition, classification and sources". Stem Cells: From Benchtop to Bedside. World Scientific. p. 5. ISBN 981-256-126-9. OCLC 443407924.{{cite book}}: CS1 maint: multiple names: editors list (link)
  18. ^ Moore, K.L., T.V.N. Persaud, and A.G. Torchia. Before We Are Born: Essentials of Embryology and Birth Defects. Philadelphia, PA: Saunders, Elsevier. 2013. Print
  19. ^ Jiang Y; Jahagirdar BN; Reinhardt RL; Schwartz, Robert E.; Keene, C. Dirk; Ortiz-Gonzalez, Xilma R.; Reyes, Morayma; Lenvik, Todd; Lund, Troy (2002). "Pluripotency of mesenchymal stem cells derived from adult marrow". Nature. 418 (6893): 41–9. doi:10.1038/nature00870. PMID 12077603.
  20. ^ "Stem Cells" Mayo Clinic. Mayo foundation for medical education and research n.d Web. March 23, 2013
  21. ^ Ratajczak MZ, Machalinski B, Wojakowski W, Ratajczak J, Kucia M (2007). "A hypothesis for an embryonic origin of pluripotent Oct-4(+) stem cells in adult bone marrow and other tissues". Leukemia. 21 (5): 860–7. doi:10.1038/sj.leu.2404630. PMID 17344915.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  22. ^ Narasipura SD; Wojciechowski, J. C.; Charles, N.; Liesveld, J. L.; King, M. R. (2008). "P-Selectin coated microtube for enrichment of CD34+ hematopoietic stem and progenitor cells from human bone marrow". Clin Chem. 54 (1): 77–85. doi:10.1373/clinchem.2007.089896. PMID 18024531.
  23. ^ William JB; Prabakaran, Rajamanickam; Ayyappan, Subbu (2011). "Functional Recovery of Spinal Cord Injury Following Application of Intralesional Bone Marrow Mononuclear Cells Embedded in Polymer Scaffold – Two Year Follow-up in a Canine". Journal of Stem Cell Research & Therapy. 01 (3). doi:10.4172/2157-7633.1000110.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  24. ^ Terai S; Ishikawa, Tsuyoshi; Omori, Kaoru; Aoyama, Koji; Marumoto, Yoshio; Urata, Yohei; Yokoyama, Yuichirou; Uchida, Koichi; Yamasaki, Takahiro (2006). "Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy". Stem Cells. 24 (10): 2292–8. doi:10.1634/stemcells.2005-0542. PMID 16778155.
  25. ^ Subrammaniyan R; Amalorpavanathan, Joseph; Shankar, Rajendran; Rajkumar, Murugesan; Baskar, Subramani; Manjunath, Sadananda Rao; Senthilkumar, Rajappa; Murugan, Palanisamy; Srinivasan, Venkaba Rao (2011). "Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a result of diabetes: our experience". Cytotherapy. 13 (8): 993–9. doi:10.3109/14653249.2011.579961. PMID 21671823.
  26. ^ Madhusankar N. "Use of Bone Marrow derived Stem Cells in Patients with Cardiovascular Disorders". Journal of Stem Cells and Regenerative Medicine.
  27. ^ Dedeepiya VD; Rao, Yegneswara Yellury; Jayakrishnan, Gosalakkal A.; Parthiban, Jutty K. B. C.; Baskar, Subramani; Manjunath, Sadananda Rao; Senthilkumar, Rajappa; Abraham, Samuel J. K. (2012). "Index of CD34+ Cells and Mononuclear Cells in the Bone Marrow of Spinal Cord Injury Patients of Different Age Groups: A Comparative Analysis". Bone Marrow Res. 2012: 787414. doi:10.1155/2012/787414. PMC 3398573. PMID 22830032.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  28. ^ Gardner RL (2002). "Stem cells: potency, plasticity and public perception". Journal of Anatomy. 200 (3): 277–82. doi:10.1046/j.1469-7580.2002.00029.x. PMC 1570679. PMID 12033732.
  29. ^ a b c Takahashi K, Yamanaka S (2006). "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors". Cell. 126 (4): 663–76. doi:10.1016/j.cell.2006.07.024. PMID 16904174.
  30. ^ Barrilleaux B, Phinney DG, Prockop DJ, O'Connor KC (2006). "Review: ex vivo engineering of living tissues with adult stem cells". Tissue Eng. 12 (11): 3007–19. doi:10.1089/ten.2006.12.3007. PMID 17518617.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  31. ^ Gimble JM, Katz AJ, Bunnell BA (2007). "Adipose-derived stem cells for regenerative medicine". Circ Res. 100 (9): 1249–60. doi:10.1161/01.RES.0000265074.83288.09. PMID 17495232.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  32. ^ "Bone Marrow Transplant".
  33. ^ Kane, Ed (2008-05-01). "Stem-cell therapy shows promise for horse soft-tissue injury, disease". DVM Newsmagazine. Retrieved 2008-06-12.
  34. ^ "Stem Cell FAQ". US Department of Health and Human Services. 2004-07-14.
  35. ^ Huang GT, Gronthos S, Shi S (2009 Sep). "Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine". J Dent Res. 88 (9): 792–806. doi:10.1177/0022034509340867. PMC 2830488. PMID 19767575. {{cite journal}}: Check date values in: |date= (help)CS1 maint: multiple names: authors list (link)
  36. ^ P. De Coppi, G Barstch, Anthony Atala (2007). "Isolation of amniotic stem cell lines with potential for therapy". Nature Biotechnology. 25 (5): 100–106. doi:10.1038/nbt1274. PMID 17206138.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  37. ^ NewsHour with Jim Lehrer. "Online NewsHour: Update | Amniotic Fluid Yields Stem Cells | January 8, 2007". PBS. Retrieved 2010-03-14.
  38. ^ Hines, Pamela J. (2008-03-21). "Public : Stem Cell Briefings". ISSCR. Retrieved 2010-03-14.
  39. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 6131275, please use {{cite journal}} with |pmid=6131275 instead.
  40. ^ "Biocell picks Massachusetts to house North American headquarters – Related Stories – BIO SmartBrief". Smartbrief.com. Retrieved 2010-03-14.
  41. ^ "Vatican newspaper calls new stem cell source 'future of medicine' :: Catholic News Agency (CNA)". Catholic News Agency. 2010-02-03. Retrieved 2010-03-14.
  42. ^ "European Biotech Company Biocell Center Opens First U.S. Facility for Preservation of Amniotic Stem Cells in Medford, Massachusetts". Reuters. 2009-10-22. Retrieved 2010-03-14.
  43. ^ "Europe's Biocell Center opens Medford office – Daily Business Update". The Boston Globe. 2009-10-22. Retrieved 2010-03-14.
  44. ^ "The Ticker". BostonHerald.com. 2009-10-22. Retrieved 2010-03-14.
  45. ^ "Biocell Center opens amniotic stem cell bank in Medford". Mass High Tech Business News. 2009-10-23. Retrieved 2012-08-26.
  46. ^ "News » World's First Amniotic Stem Cell Bank Opens In Medford". wbur.org. Retrieved 2010-03-14.
  47. ^ "Biocell Center Corporation Partners with New England's Largest Community-Based Hospital Network to Offer a Unique... – MEDFORD, Mass., March 8 /PRNewswire/". Massachusetts: Prnewswire.com. Retrieved 2010-03-14.
  48. ^ a b c d e Zhao, Yong; Wang, Honglan and Mazzone, Theodore (2006 Aug 1). "Identification of stem cells from human umbilical cord blood with embryonic and hematopoietic characteristics" (PDF). Exp Cell Res. 312 (13): 2454–2464. doi:10.1016/j.yexcr.2006.04.008. PMID 16716296. {{cite journal}}: Check date values in: |date= (help)CS1 maint: multiple names: authors list (link)
  49. ^ a b c Zhao, Yong; Lin, Brian; Darflinger, Robert; Zhang, Yongkang; Holterman, Mark J. and Skidgel, Randal A. (2009 January 19). Unutmaz, Derya (ed.). "Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice" (PDF). PLoS ONE. 4 (1): e4226. doi:10.1371/journal.pone.0004226. PMC 2627485. PMID 19156219. {{cite journal}}: Check date values in: |date= (help)CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  50. ^ a b c Zhao, Yong; Wang, Honglan and Mazzone, Theodore (2007). "Immune regulation of T lymphocyte by a newly characterized human umbilical cord blood stem cell" (PDF). Immunol Lett. 108 (1): 78–87. doi:10.1016/j.imlet.2006.10.007. PMID 17161871.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  51. ^ a b Yong Zhao, Theodore Mazzone (2010). "Human cord blood stem cells and the journey to a cure for type 1 diabetes" (PDF). Autoimmun Rev. 10 (2): 103–107. doi:10.1016/j.autrev.2010.08.011. PMID 20728583.
  52. ^ a b Zhao Y, Lin B, Dingeldein M, Guo C, Hwang D, Holterman MJ. (2010 May). "New type of human blood stem cell: a double-edged sword for the treatment of type 1 diabetes" (PDF). Transl Res. 155 (5): 211–216. doi:10.1016/j.trsl.2010.01.003. PMID 20403575. {{cite journal}}: Check date values in: |year= (help)CS1 maint: multiple names: authors list (link) CS1 maint: year (link)
  53. ^ a b Yong Zhao, Zhaoshun Jiang, Tingbao Zhao, Mingliang Ye, Chengjin Hu, Zhaohui Yin, Heng Li, Ye Zhang, Yalin Diao, Yunxiang Li, Yingjian Chen, Xiaoming Sun, Mary Beth Fisk, Randal Skidgel, Mark Holterman, Bellur Prabhakar, Theodore Mazzone (2012 Jan 10). "Reversal of type 1 diabetes via islet ß cell regeneration following immune modulation by cord blood-derived multipotent stem cells" (PDF). BMC Medicine 2012. 10: 1–11. doi:10.1186/1741-7015-10-3. PMC 3322343. PMID 22233865. {{cite journal}}: Check date values in: |year= (help)CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link) CS1 maint: year (link)
  54. ^ a b Yong Zhao (2012 Oct). "Stem cell educator therapy and induction of immune balance" (PDF). Curr Diab Rep. 12 (5): 517–523. doi:10.1007/s11892-012-0308-1. PMID 22833322. {{cite journal}}: Check date values in: |year= (help)CS1 maint: year (link)
  55. ^ a b c "Making human embryonic stem cells". The Economist. 2007-11-22.
  56. ^ Brand, Madeleine; Palca, Joe and Cohen, Alex (2007-11-20). "Skin Cells Can Become Embryonic Stem Cells". National Public Radio.{{cite web}}: CS1 maint: multiple names: authors list (link)
  57. ^ "Breakthrough Set to Radically Change Stem Cell Debate". News Hour with Jim Lehrer. 2007-11-20.
  58. ^ "His inspiration comes from the research by Prof Shinya Yamanaka at Kyoto University, which suggests a way to create human embryo stem cells without the need for human eggs, which are in extremely short supply, and without the need to create and destroy human cloned embryos, which is bitterly opposed by the pro life movement."Highfield, Roger (2007-11-16). "Dolly creator Prof Ian Wilmut shuns cloning". London: The Telegraph.
  59. ^ Frozen blood a source of stem cells, study finds. newsdaily.com (2010-07-01)
  60. ^ Beckmann J, Scheitza S, Wernet P, Fischer JC, Giebel B (2007). "Asymmetric cell division within the human hematopoietic stem and progenitor cell compartment: identification of asymmetrically segregating proteins". Blood. 109 (12): 5494–501. doi:10.1182/blood-2006-11-055921. PMID 17332245.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  61. ^ Xie T, Spradling A (1998). "decapentaplegic is essential for the maintenance and division of germline stem cells in the Drosophila ovary". Cell. 94 (2): 251–60. doi:10.1016/S0092-8674(00)81424-5. PMID 9695953.
  62. ^ Song X, Zhu C, Doan C, Xie T (2002). "Germline stem cells anchored by adherens junctions in the Drosophila ovary niches". Science. 296 (5574): 1855–7. doi:10.1126/science.1069871. PMID 12052957.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  63. ^ Vierbuchen T, Ostermeier A, Pang ZP, Kokubu Y, Südhof TC, Wernig M (2010-02-25). "Direct conversion of fibroblasts to functional neurons by defined factors". Nature. 463 (7284): 1035–41. doi:10.1038/nature08797. PMC 2829121. PMID 20107439. {{cite journal}}: Unknown parameter |laysummary= ignored (help)CS1 maint: multiple names: authors list (link)
  64. ^ Diabetes, rheumatoid arthritis, Parkinson's, Alzheimer's disease, osteoarthritis: Stroke and traumatic brain injury repair: Learning defects: Spinal cord injury repair:
    • Kang KS; Kim SW; Oh YH; Yu, JW; Kim, K-Y; Park, HK; Song, C-H; Han, H (2005). "A 37-year-old spinal cord-injured female patient, transplanted of multipotent stem cells from human UC blood, with improved sensory perception and mobility, both functionally and morphologically: a case study". Cytotherapy. 7 (4): 368–73. doi:10.1080/14653240500238160. PMID 16162459.
    Heart infarction:
    • Strauer BE, Schannwell CM, Brehm M (2009). "Therapeutic potentials of stem cells in cardiac diseases". Minerva Cardioangiol. 57 (2): 249–67. PMID 19274033.{{cite journal}}: CS1 maint: multiple names: authors list (link)
    Anti-cancer: Baldness: Replace missing teeth: Repair hearing: Restore vision: Amyotrophic lateral sclerosis:
    • Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1001/jama.285.13.1691, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1001/jama.285.13.1691 instead.
    Crohn's disease: Wound healing:
  65. ^ Gahrton G, Björkstrand B (2000). "Progress in haematopoietic stem cell transplantation for multiple myeloma". J Intern Med. 248 (3): 185–201. doi:10.1046/j.1365-2796.2000.00706.x. PMID 10971785.
  66. ^ Lindvall O (2003). "Stem cells for cell therapy in Parkinson's disease". Pharmacol Res. 47 (4): 279–87. doi:10.1016/S1043-6618(03)00037-9. PMID 12644384.
  67. ^ Goldman S, Windrem M (2006). "Cell replacement therapy in neurological disease". Philos Trans R Soc Lond B Biol Sci. 361 (1473): 1463–75. doi:10.1098/rstb.2006.1886. PMC 1664668. PMID 16939969.
  68. ^ "Stem-cell therapy: Promise and reality." Consumer Reports on Health 17.6 (2005): 8–9. Academic Search Premier. EBSCO. Web. 5 Apr. 2010.
  69. ^ Wade N (2006-08-14). "Some Scientists See Shift in Stem Cell Hopes". New York Times. Retrieved 2006-12-28.
  70. ^ Moore, Keith L., T.V.N. Persaud, and Mark G. Torchia. Before We Are Born: Essentials of Embryology and Birth Defects. Philadelphia, PA: Saunders, Elsevier. 2013 Print.
  71. ^ Greenhough S, Hay DC. (2012). "Stem Cell-Based Toxicity Screening: Recent Advances in Hepatocyte Generation". Pharm Med. 26 (2): 85–89. doi:10.1007/BF03256896.
  72. ^ Regalado, Antonio, David P. Hamilton (July 2006). "How a University's Patents May Limit Stem-Cell Researcher." The Wall Street Journal. Retrieved on July 24, 2006.
  73. ^ Kintisch, Eli (2006-07-18) "Groups Target Stem Cell Patents." ScienceNOW Daily News. Retrieved August 15, 2006.
  74. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 10085391, please use {{cite journal}} with |pmid=10085391 instead.
  75. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 1767543, please use {{cite journal}} with |pmid=1767543 instead.
  76. ^ Maingot, Rodney (1997). Abdominal Operations. ISBN 0838561063.
  77. ^ Textbook of Gynaecology. JP Publications. 2010. pp. 620–625. ISBN 9350253690.
  78. ^ Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM (1998). "Embryonic stem cell lines derived from human blastocysts". Science. 282 (5391). New York: 1145–7. doi:10.1126/science.282.5391.1145. PMID 9804556.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  79. ^ Cibelli JB, Lanza RP, West MD, Ezzell C (2001). "The first human cloned embryo". Scientific American. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  80. ^ Shostak S (2006). "(Re)defining stem cells". BioEssays. 28 (3): 301–8. doi:10.1002/bies.20376. PMID 16479584.
  81. ^ Keirstead, HS (2005). "Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury". The Journal of Neuroscience. 25 (19): 4694–4705. doi:10.1523/JNEUROSCI.0311-05.2005. PMID 15888645. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  82. ^ "Good news for alcoholics". Discover Magazine. 2007. Retrieved 2010-02-28. {{cite web}}: Unknown parameter |month= ignored (help)
  83. ^ Ross, Shã‚N (2006-10-31). "First liver grown from stem cells offers hope for transplant patients". Edinburgh: The Scotsman. Archived from the original on 2007-02-03. {{cite news}}: C1 control character in |first= at position 4 (help)
  84. ^ De Coppi P; Bartsch G; Siddiqui MM; Xu, Tao; Santos, Cesar C; Perin, Laura; Mostoslavsky, Gustavo; Serre, Angéline C; Snyder, Evan Y (2007). "Isolation of amniotic stem cell lines with potential for therapy". Nat Biotechnol. 25 (1): 100–6. doi:10.1038/nbt1274. PMID 17206138.
  85. ^ Kaplan, Karen (8 January 2007). "Easy stem-cell source sparks interest: Researchers find amniotic fluid offers advantages". Boston Globe.
  86. ^ Cyranoski D (2007). "Simple switch turns cells embryonic". Nature. 447 (7145): 618–9. doi:10.1038/447618a. PMID 17554270.
  87. ^ Mitalipov SM, Zhou Q, Byrne JA, Ji WZ, Norgren RB, Wolf DP (2007). "Reprogramming following somatic cell nuclear transfer in primates is dependent upon nuclear remodeling". Hum Reprod. 22 (8): 2232–42. doi:10.1093/humrep/dem136. PMID 17562675.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  88. ^ "The Nobel prize in physiology or medicine 2007". Nobelprize.org. Retrieved 8 October 2007.
  89. ^ Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007). "Induction of pluripotent stem cells from adult human fibroblasts by defined factors" (PDF). Cell. 131 (5): 861–72. doi:10.1016/j.cell.2007.11.019. PMID 18035408.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  90. ^ Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA (2007). "Induced pluripotent stem cell lines derived from human somatic cells". Science. 318 (5858): 1917–20. doi:10.1126/science.1151526. PMID 18029452.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  91. ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1016/j.stem.2007.12.013, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1016/j.stem.2007.12.013 instead.
  92. ^ French AJ, Adams CA, Anderson LS, Kitchen JR, Hughes MR, Wood SH (2008). "Development of human cloned blastocysts following somatic cell nuclear transfer (SCNT) with adult fibroblasts" (PDF). Stem Cells Express. 26 (2): 485–93. doi:10.1634/stemcells.2007-0252. PMID 18202077. Archived from the original (PDF) on 2008-06-25.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  93. ^ Aoi T; Yae K; Nakagawa M; Ichisaka, T.; Okita, K.; Takahashi, K.; Chiba, T.; Yamanaka, S. (2008). "Generation of pluripotent stem cells from adult mouse liver and stomach cells". Science. 321 (5889): 699–702. doi:10.1126/science.1154884. PMID 18276851.
  94. ^ Centeno CJ, Busse D, Kisiday J, Keohan C, Freeman M, Karli D (2008). "Increased knee cartilage volume in degenerative joint disease using percutaneously implanted, autologous mesenchymal stem cells". Pain Physician. 11 (3): 343–53. ISSN 1533-3159. PMID 18523506.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  95. ^ Conrad S; Renninger M; Hennenlotter J; Wiesner, Tina; Just, Lothar; Bonin, Michael; Aicher, Wilhelm; Bühring, Hans-Jörg; Mattheus, Ulrich (2008). "Generation of pluripotent stem cells from adult human testis". Nature. 456 (7220): 344–9. doi:10.1038/nature07404. PMID 18849962.
  96. ^ Baker M (2008). "Embryonic-like stem cells from a single human hair". Nature Reports Stem Cells. doi:10.1038/stemcells.2008.142.
  97. ^ Woltjen K, Michael IP, Mohseni P, Desai R, Mileikovsky M, Hämäläinen R, Cowling R, Wang W, Liu P, Gertsenstein M, Kaji K, Sung HK, Nagy A (2009-03-01). "piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells". Nature. 458 (7239): 766–70. doi:10.1038/nature07863. PMID 19252478.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  98. ^ "Canadians make stem cell breakthrough". March 1, 2009. Retrieved March 1, 2009.
  99. ^ "Researchers find new method for turning adult cells into stem cells". Amherst Daily News. Canadian Press. 2009-01-03. Retrieved 2010-02-28.
  100. ^ a b Sample, Ian (2009-03-01). "Scientists' stem cell breakthrough ends ethical dilemma". London: The Guardian. Retrieved 2009-03-03.
  101. ^ Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K (2009). "Virus-free induction of pluripotency and subsequent excision of reprogramming factors". Nature. 458 (7239): 771–5. doi:10.1038/nature07864. PMC 2667910. PMID 19252477.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  102. ^ Lee ASJ, Kahatapitiya P, Kramer B, Joya JE, Hook J, Liu R, Schevzov G, Alexander IE, McCowage G, Montarras D, Gunning PW, Hardeman EC (2009). "Methylguanine DNA methyltransferase-mediated drug resistance-based selective enrichment and engraftment of transplanted stem cells in skeletal muscle". Stem Cells. 27 (5): 1098–1108. doi:10.1002/stem.28. PMID 19415780.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  103. ^ Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS, Ko S, Yang E, Cha KY, Lanza R, Kim KS (27 May 2009). "Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins". Cell Stem Cell. 4 (6): 472–6. doi:10.1016/j.stem.2009.05.005. PMC 2705327. PMID 19481515. {{cite journal}}: Unknown parameter |laysummary= ignored (help)CS1 maint: multiple names: authors list (link) (cited in lay summary, not read)
  104. ^ "First trial of embryonic stem cells in humans". BBC News. 2010-10-11.
  105. ^ Ishikawa K, Toyama-Sorimachi N, Nakada K, Morimoto M, Imanishi H, Yoshizaki M, Sasawatari S, Niikura M, Takenaga K, Yonekawa H, Hayashi J (2010). "The innate immune system in host mice targets cells with allogenic mitochondrial DNA". J Exp Med. 207 (11): 2297–305. doi:10.1084/jem.20092296. PMC 2964578. PMID 20937705.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  106. ^ Shtull-Trauring, Asaf (2011-09-06) Israeli scientist leads breakthrough stem cell research on endangered species
  107. ^ Gordon, Serena (January 13, 2012). "USA Today". Novel stem cell treatment may hold promise for type 1 diabetes. Retrieved December 11, 2012.
  108. ^ Teif VB, Vainshtein Y, Caudron-Herger M, Mallm JP, Marth C, Höfer T, Rippe K. (2012). "Genome-wide nucleosome positioning during embryonic stem cell development". Nat Struct Mol Biol. 19 (11): 1185–92. doi:10.1038/nsmb.2419. PMID 23085715.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  109. ^ Attention: This template ({{cite doi}}) is deprecated. To cite the publication identified by doi:10.1126/science.1226889, please use {{cite journal}} (if it was published in a bona fide academic journal, otherwise {{cite report}} with |doi=10.1126/science.1226889 instead.
  110. ^ http://www.theguardian.com/science/2013/aug/05/lab-grown-hamburger-synthetic-meat
  111. ^ http://www.nature.com/news/stem-cells-created-in-living-mice-1.13725
Wikimedia Commons has media related to Stem cells.
General
Peer-reviewed journals
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Stem_cell&oldid=582406993"